



Diagnosis and Treatment of Malignant Bone Tumors

Guest Editor:

Dr. Shinji Miwa

Department of Orthopedic
Surgery, Graduate School of
Medical Science, Kanazawa
University, Kanazawa, Japan

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues,

Malignant bone tumors require intensive treatments, including chemotherapy, surgical tumor excision, and radiation therapy. Although limb-salvage surgery is standard treatment for malignant bone tumors, there remains various problems such as limited options of anticancer agents, postoperative surgical site infections, breakage of tumor prosthesis, and fracture of transplanted bone. To improve oncological and functional outcomes of malignant bone tumors, improvement of diagnostic method, selection of appropriate anticancer drugs, development of new anticancer drugs, improvement of surgical techniques and implants, are demanded. This Special Issue of Cancers aims to bring together the highest quality original/review articles on clinical research for malignant bone tumors.

Dr. Shinji Miwa
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)